{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:37:08Z","timestamp":1791247028759,"version":"4.1.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.1001\/jamacardio.2021.1437","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T18:20:39Z","timestamp":1622053239000},"page":"926","source":"Crossref","is-referenced-by-count":97,"title":["Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1001","volume":"6","author":[{"given":"Justin T.","family":"Parizo","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Goldhaber-Fiebert","sequence":"additional","affiliation":[{"name":"Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, The Freeman Spogli Institute, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Salomon","sequence":"additional","affiliation":[{"name":"Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, The Freeman Spogli Institute, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran K.","family":"Khush","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[{"name":"St Luke\u2019s Mid America Heart Institute, University of Missouri\u2013Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Cardiology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"hoi210030r1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"3","key":"hoi210030r2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jama.292.3.344","article-title":"Trends in heart failure incidence and survival in a community-based population.","volume":"292","author":"Roger","year":"2004","journal-title":"JAMA"},{"issue":"10","key":"hoi210030r3","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association.","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"22","key":"hoi210030r4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"hoi210030r5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi210030r6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"hoi210030r7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"hoi210030r8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi210030r10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial.","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"hoi210030r11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme.","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"issue":"14","key":"hoi210030r12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes.","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"hoi210030r13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjcard.2006.08.065","article-title":"A propensity matched study of New York Heart Association class and natural history end points in heart failure.","volume":"99","author":"Ahmed","year":"2007","journal-title":"Am J Cardiol"},{"issue":"3","key":"hoi210030r14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jchf.2015.10.015","article-title":"Utility of patient-reported outcome instruments in heart failure.","volume":"4","author":"Kelkar","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"15","key":"hoi210030r15","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1161\/CIRCULATIONAHA.106.670901","article-title":"Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments.","volume":"115","author":"Kosiborod","year":"2007","journal-title":"Circulation"},{"issue":"10","key":"hoi210030r16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jchf.2019.06.006","article-title":"Patient-reported outcomes: the future of heart failure care.","volume":"7","author":"Heidenreich","year":"2019","journal-title":"JACC Heart Fail"},{"key":"hoi210030r17","doi-asserted-by":"crossref","DOI":"10.1093\/ehjqcco\/qcab014","article-title":"Predicting the EQ-5D from the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failure.","author":"Thomas","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"11","key":"hoi210030r18","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ejhf.v21.11","article-title":"The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"25","key":"hoi210030r19","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1016\/j.jacc.2019.10.020","article-title":"Health-related quality of life in comorbid heart failure with reduced ejection fraction and diabetes mellitus.","volume":"74","author":"Vaduganathan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi210030r20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ejhf.2016.18.issue-3","article-title":"The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF.","volume":"18","author":"Ambrosy","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hoi210030r21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ahj.2014.11.007","article-title":"Factors associated with variations in hospital expenditures for acute heart failure in the United States.","volume":"169","author":"Ziaeian","year":"2015","journal-title":"Am Heart J"},{"issue":"8","key":"hoi210030r22","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.amjcard.2012.05.059","article-title":"In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial).","volume":"110","author":"Reed","year":"2012","journal-title":"Am J Cardiol"},{"issue":"22","key":"hoi210030r24","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1161\/CIR.0000000000000042","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.","volume":"129","author":"Anderson","year":"2014","journal-title":"Circulation"},{"issue":"19","key":"hoi210030r25","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.ehj.2004.07.007","article-title":"Effect of age on short and long-term mortality in patients admitted to hospital with congestive heart failure.","volume":"25","author":"Gustafsson","year":"2004","journal-title":"Eur Heart J"},{"issue":"9","key":"hoi210030r26","first-page":"1","article-title":"United States life tables eliminating certain causes of death, 1999-2001.","volume":"61","author":"Arias","year":"2013","journal-title":"Natl Vital Stat Rep"},{"issue":"11","key":"hoi210030r27","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/ejhf.v22.11","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"hoi210030r28","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association.","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"hoi210030r29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction.","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"hoi210030r30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.healun.2017.07.005","article-title":"Eighth annual INTERMACS report: special focus on framing the impact of adverse events.","volume":"36","author":"Kirklin","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"hoi210030r32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jval.2017.06.013","article-title":"A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses.","volume":"21","author":"Levy","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"hoi210030r33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1161\/CIRCOUTCOMES.110.957225","article-title":"Lifetime costs of medical care after heart failure diagnosis.","volume":"4","author":"Dunlay","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"hoi210030r34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ahj.2006.11.010","article-title":"Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study.","volume":"153","author":"Liao","year":"2007","journal-title":"Am Heart J"},{"issue":"8","key":"hoi210030r35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.7326\/L17-0044","article-title":"Cost-effectiveness of sacubitril-valsartan in patients who have heart failure with reduced ejection fraction.","volume":"166","author":"Sandhu","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"hoi210030r38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jval.2015.02.003","article-title":"Determinants of utility based on the EuroQol Five-Dimensional Questionnaire in patients with chronic heart failure and their change over time: results from the Swedish Heart Failure Registry.","volume":"18","author":"Berg","year":"2015","journal-title":"Value Health"},{"issue":"10","key":"hoi210030r39","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/archinte.158.10.1081","article-title":"Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival.","volume":"158","author":"Jaagosild","year":"1998","journal-title":"Arch Intern Med"},{"issue":"2","key":"hoi210030r40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.healun.2012.12.004","article-title":"Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients","volume":"32","author":"Kirklin","year":"2013","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"hoi210030r41","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.healun.2006.09.011","article-title":"Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the Evaluation of Ventricular Assist Device Programme in the UK (EVAD-UK).","volume":"25","author":"Sharples","year":"2006","journal-title":"J Heart Lung Transplant"},{"issue":"53","key":"hoi210030r42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17530","article-title":"Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.","volume":"17","author":"Sutcliffe","year":"2013","journal-title":"Health Technol Assess"},{"issue":"11","key":"hoi210030r43","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi210030r44","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4330\/wjc.v7.i11.792","article-title":"Short and long term outcomes of 200 patients supported by continuous-flow left ventricular assist devices.","volume":"7","author":"Tsiouris","year":"2015","journal-title":"World J Cardiol"},{"issue":"s1","key":"hoi210030r45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ajt.v20.s1","article-title":"OPTN\/SRTR 2018 annual data report: preface.","volume":"20","year":"2020","journal-title":"Am J Transplant"},{"issue":"5","key":"hoi210030r46","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006505","article-title":"Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey.","volume":"5","author":"Hutchins","year":"2015","journal-title":"BMJ Open"},{"issue":"24","key":"hoi210030r47","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1161\/CIRCULATIONAHA.113.007595","article-title":"Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility.","volume":"129","author":"Fontana","year":"2014","journal-title":"Circulation"},{"issue":"10254","key":"hoi210030r48","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"hoi210030r49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cardfail.2008.01.014","article-title":"A comparison of patient and physician-rated New York Heart Association class in a community-based heart failure clinic.","volume":"14","author":"Goode","year":"2008","journal-title":"J Card Fail"},{"issue":"3","key":"hoi210030r50","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1161\/CIRCULATIONAHA.108.820472","article-title":"Patient health status and costs in heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).","volume":"119","author":"Chan","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"hoi210030r51","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/hrt.2006.089656","article-title":"Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure.","volume":"93","author":"Raphael","year":"2007","journal-title":"Heart"},{"key":"hoi210030r52","doi-asserted-by":"crossref","DOI":"10.1177\/2047487320938272","article-title":"Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective.","author":"Savira","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"hoi210030r53","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1002\/ehf2.v7.6","article-title":"Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China.","volume":"7","author":"Yao","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"15","key":"hoi210030r54","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"hoi210030r9","unstructured":"Centers for Medicare & Medicaid Services. Part D Prescriber Data CY 2018. Modified December 3, 2020. Accessed February 9, 2021. https:\/\/www.cms.gov\/research-statistics-data-systems\/medicare-provider-utilization-and-payment-data\/medicare-provider-utilization-and-payment-data-part-d-prescriber\/part-d-prescriber-data-cy-2018"},{"key":"hoi210030r23","doi-asserted-by":"crossref","unstructured":"Neumann? PJ, Ganiats? TG, Russell? LB, Sanders? GD, Siegel? JE. Cost-effectiveness in Health and Medicine. 2nd ed. Oxford University Press; 2016. Accessed October 11, 2020. https:\/\/oxford.universitypressscholarship.com\/view\/10.1093\/acprof:oso\/9780190492939.001.0001\/acprof-9780190492939","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001"},{"key":"hoi210030r31","unstructured":"Scientific Registry of Transplant Recipients. The SRTR\/OPTN Annual Data Report. Published February 17, 2021. Accessed February 27, 2021. https:\/\/www.srtr.org\/reports-tools\/srtroptn-annual-data-report\/"},{"key":"hoi210030r36","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule. Updated April 1, 2021. Accessed June 18, 2020. https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/physicianfeesched?redirect=\/physicianfeesched"},{"key":"hoi210030r37","unstructured":"National Data (National Income and Product Accounts). Price Indexes for Personal Consumption Expenditures by Major Type of Product and by Major Function. Accessed September 17, 2020. https:\/\/apps.bea.gov\/iTable\/iTable.cfm?reqid=19&step=2#reqid=19&step=2&isuri=1&1921=underlying"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2780359\/jamacardiology_parizo_2021_oi_210030_1628256747.87722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T20:07:15Z","timestamp":1628539635000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2780359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2021.1437","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}